

# The RALLY study: dose finding study for radiation lobectomy using holmium-166 microspheres to improve resectability in patients with HCC.

Gepubliceerd: 15-09-2020 Laatste bijgewerkt: 15-05-2024

Holmium-166 radiation lobectomy is a safe method to bridge patients with HCC to resection.

|                             |                       |
|-----------------------------|-----------------------|
| <b>Ethische beoordeling</b> | Positief advies       |
| <b>Status</b>               | Werving gestart       |
| <b>Type aandoening</b>      | -                     |
| <b>Onderzoekstype</b>       | Interventie onderzoek |

## Samenvatting

### ID

NL-OMON23909

### Bron

Nationaal Trial Register

### Verkorte titel

RALLY

### Aandoening

Hepatocellular Carcinoma

## Ondersteuning

**Primaire sponsor:** UMC Utrecht

**Overige ondersteuning:** Terumo

## Onderzoeksproduct en/of interventie

## Uitkomstmaten

### Primaire uitkomstmaten

To establish the maximum tolerated healthy liver-absorbed dose of  $^{166}\text{Ho}$ -microspheres in patients with HCC who receive radiation lobectomy as a bridge to surgery.

## Toelichting onderzoek

### Achtergrond van het onderzoek

Radiation lobectomy as a means of controlling tumour growth while concomitantly inducing future liver remnant (FLR) hypertrophy has recently gained interest to convert unresectable hepatocellular carcinoma (HCC) patients. Dosimetry is of major importance here, since particularly healthy liver-absorbed dose drives FLR response. However, current techniques using yttrium-90 ( $^{90}\text{Y}$ ) beta-radiation emitting microspheres cannot be visualised properly. This makes it difficult to accurately predict healthy liver-absorbed dose. Radiation lobectomy using holmium-166 ( $^{166}\text{Ho}$ ) offers a potentially more safe, effective and personal treatment modality, due to its variety of imaging options. However, the acceptable toxicity dose profile of  $^{166}\text{Ho}$  on healthy liver tissue in this setting is unknown.

### Doel van het onderzoek

Holmium-166 radiation lobectomy is a safe method to bridge patients with HCC to resection.

### Onderzoeksopzet

T1: Screening

T2: Radiation lobectomy

T3: Post radiation lobectomy follow-up visits (at 1.5, 3, 4.5, 6 and 9 months after radiation lobectomy or until resection is feasible).

T4: Surgery

T5: Post surgery follow-up visit (3 months after surgery)

### Onderzoeksproduct en/of interventie

Holmium-166 radiation lobectomy

## Contactpersonen

### Publiek

UMC Utrecht

Inne Borel Rinkes

+31 88 75 580 74

## Wetenschappelijk

UMC Utrecht  
Inne Borel Rinkes

+31 88 75 580 74

## Deelname eisen

### Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)

In order to be eligible to participate in this study (including the biobank), a subject must meet all of the following criteria:

- 1) Patients must have given written informed consent.
- 2) Age  $\geq$  18 years.
- 3) ECOG Performance status 0-1.
- 4) Diagnosis of HCC, established according to the Netherlands HCC guideline criteria (in line with American AASLD criteria): nodule  $>1$  cm in a patient at risk for HCC, with combination of arterial hypervascularity and venous or delayed phase wash-out on multiphase CT-scan or MRI-scan.
- 5) HCC with indication for major hepatectomy (i.e.,  $>2$  segments), as decided by multidisciplinary tumour board.
- 6) Hepatobiliary scintigraphy  $> 1.5\%/min/m^2$  and  $< 2.7 \%/min/m^2$ .
- 7) Negative pregnancy test for women of childbearing potential. Female patients of childbearing potential should use a highly effective acceptable method of contraception (oral contraceptives, barrier methods, approved contraceptive implant, long-term injectable contraception, intrauterine device or tubal ligation) or should be more than one year postmenopausal or surgically sterile during their participation in this study (from the time they sign the consent form), to prevent pregnancy.
- 8) Patients with compensated Child-Pugh A and unilobar BCLC-B or less (without evidence of portal hypertension).

### Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)

A potential subject who meets any of the following criteria will be excluded from participation in this study:

- 1) Evidence of extrahepatic disease (MRI-scan liver and multiphase abdominal CT as well as a thoracic CT are routinely performed at screening).
- 2) Any previous hepatic external beam radiation therapy before the start of study therapy.
- 3) Previous treatment with radioembolization/radiation lobectomy.
- 4) Major surgery within 4 weeks or incompletely healed surgical incision before starting study therapy.
- 5) Glomerular filtration rate  $<35$  ml/min, determined according to the Modification of Diet in Renal Disease formula.
- 6) Non correctable INR  $> 1.5$ .
- 7) Significant cardiac event (e.g., myocardial infarction, superior vena cava syndrome, New York Heart Association (NYHA) classification of heart disease  $\geq 2$  within 3 months before entry, or presence of cardiac disease that in the opinion of the investigator increases the risk of ventricular arrhythmia.
- 8) Pregnancy or breastfeeding.
- 9) Patients suffering from psychic disorders that make a comprehensive judgment impossible, such as psychosis, hallucinations and/or depression.
- 10) Patients who are declared incompetent.
- 11) Previous enrolment in the present study.
- 12) Patients who do not use an acceptable method of contraception during their participation in this study (from the time they sign the consent form) to prevent pregnancy. In case of female: are less than 1 year postmenopausal and not using an acceptable method of contraception. Patients who had surgical sterilization may be included.
- 13) Any contraindication precluding surgery, with the exception of insufficient FLR as defined by hepatobiliary scintigraphy.
- 14) Portal vein thrombosis (tumour and/or bland) (diagnosed on contrast enhanced transaxial images).
- 15) Untreated active hepatitis. In case of detectable viral hepatitis B virus load, treatment with a nucleos(t)ide analog such as entecavir or tenofovir should be instituted.
- 16) Transjugular intrahepatic portosystemic shunt.
- 17) Body weight over 150 kg (because of maximum table load).
- 18) Severe allergy for intravenous contrast (Visipaque®).
- 19) Lung shunt  $> 30$  Gy, as calculated using  $^{166}\text{Ho}$ -microspheres scout dose using SPECT/CT.
- 20) Not correctable extrahepatic deposition of scout dose activity. Activity in the falciform ligament, portal lymph nodes and gallbladder is accepted.
- 21) Any systemic therapy (including transcatheter arterial chemoembolization) prior to the start of study therapy. Radiofrequency ablation or previous resection ( $> 4$  weeks) is accepted.
- 22) Leukocytes  $<2 \times 10^9/\text{L}$  and/or platelet count  $<50 \times 10^9/\text{L}$ . Serum bilirubin  $>34.2$  micromol/L (2 mg/dL).

## Onderzoeksopzet

## Opzet

|                  |                         |
|------------------|-------------------------|
| Type:            | Interventie onderzoek   |
| Onderzoeksmodel: | Anders                  |
| Toewijzing:      | N.v.t. / één studie arm |
| Blinding:        | Open / niet geblindeerd |
| Controle:        | N.v.t. / onbekend       |

## Deelname

|                         |                      |
|-------------------------|----------------------|
| Nederland               |                      |
| Status:                 | Werving gestart      |
| (Verwachte) startdatum: | 22-09-2021           |
| Aantal proefpersonen:   | 24                   |
| Type:                   | Verwachte startdatum |

## Voornemen beschikbaar stellen Individuele Patiënten Data (IPD)

**Wordt de data na het onderzoek gedeeld:** Nee

## Ethische beoordeling

|                 |                  |
|-----------------|------------------|
| Positief advies |                  |
| Datum:          | 15-09-2020       |
| Soort:          | Eerste indiening |

## Registraties

### Opgevolgd door onderstaande (mogelijk meer actuele) registratie

ID: 54237  
Bron: ToetsingOnline  
Titel:

### Andere (mogelijk minder actuele) registraties in dit register

Geen registraties gevonden.

## In overige registers

| Register | ID             |
|----------|----------------|
| NTR-new  | NL8902         |
| CCMO     | NL75713.041.21 |
| OMON     | NL-OMON54237   |

## Resultaten